Thibaut Mongon, Kenvue CEO (Brendan McDermid/Reuters)
October 22, 2024 03:35 PM EDT
Pharma

Star­board­'s Ken­vue com­plaints are much dif­fer­ent than those aimed at Pfiz­er

Max Bayer

Pharma Reporter

Star­board Val­ue, the ac­tivist in­vestor push­ing for changes at Pfiz­er, un­veiled its goals for an­oth­er health­care com­pa­ny — John­son & John­son’s con­sumer spin­out Ken­vue.

In a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times